追蹤
Rajgokul K Shanmugam
Rajgokul K Shanmugam
Research Scientist, ICGEB
在 icgeb.res.in 的電子郵件地址已通過驗證 - 首頁
標題
引用次數
引用次數
年份
Role of RNA interference (RNAi) in dengue virus replication and identification of NS4B as an RNAi suppressor
PK Kakumani, SS Ponia, V Sood, M Chinnappan, AC Banerjea, ...
Journal of virology 87 (16), 8870-8883, 2013
2312013
Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine
R Shukla, V Ramasamy, RK Shanmugam, R Ahuja, N Khanna
Frontiers in cellular and infection microbiology 10, 572681, 2020
1572020
A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which …
V Ramasamy, U Arora, R Shukla, A Poddar, RK Shanmugam, LJ White, ...
PLoS neglected tropical diseases 12 (1), e0006191, 2018
772018
Bispidine-amino acid conjugates act as a novel scaffold for the design of antivirals that block Japanese encephalitis virus replication
V Haridas, KS Rajgokul, S Sadanandan, T Agrawal, V Sharvani, ...
PLoS neglected tropical diseases 7 (1), e2005, 2013
482013
Dengue NS3, an RNAi suppressor, modulates the human miRNA pathways through its interacting partner
PK Kakumani, KS Rajgokul, SS Ponia, I Kaur, S Mahanty, GR Medigeshi, ...
Biochemical Journal 471 (1), 89-99, 2015
372015
Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models
R Shukla, H Beesetti, JA Brown, R Ahuja, V Ramasamy, RK Shanmugam, ...
EBioMedicine 60, 2020
232020
Pichia pastoris-expressed Zika virus envelope domain III on a virus-like particle platform: design, production and immunological evaluation
RK Shanmugam, V Ramasamy, R Shukla, U Arora, S Swaminathan, ...
Pathogens and disease 77 (3), ftz026, 2019
232019
Cocculus hirsutus-Derived Phytopharmaceutical Drug Has Potent Anti-dengue Activity
R Shukla, RK Rajpoot, A Poddar, R Ahuja, H Beesetti, RK Shanmugam, ...
Frontiers in Microbiology 12, 746110, 2021
152021
Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement
R Shukla, RK Shanmugam, V Ramasamy, U Arora, G Batra, JA Acklin, ...
EBioMedicine 54, 2020
132020
Association of HADHA with human RNA silencing machinery
PK Kakumani, RK Shanmugam, I Kaur, P Malhotra, SK Mukherjee, ...
Biochemical and Biophysical Research Communications 466 (3), 481-485, 2015
112015
Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine. Front Cell Infect Microbiol 10: 572681
R Shukla, V Ramasamy, RK Shanmugam, R Ahuja, N Khanna
62020
Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine. Front Cell Infect Microbiol. 2020; 10: 572681
R Shukla, V Ramasamy, RK Shanmugam, R Ahuja, N Khanna
Epub 2020/11/17. https://doi. org/10.3389/fcimb. 2020.572681 PMID: 33194810, 2020
52020
Interaction of dengue NS3 with human RNA silencing machinery through HSPA1A
PK Kakumani, RK Shanmugam, M Chinnappan, I Kaur, AP Chopra, ...
bioRxiv, 2020.06. 08.140590, 2020
12020
Correction: Bispidine-Amino Acid Conjugates Act as a Novel Scaffold for the Design of Antivirals That Block Japanese Encephalitis Virus Replication
V Haridas, KS Rajgokul, S Sadanandan, T Agrawal, V Sharvani, ...
PLOS Neglected Tropical Diseases 18 (1), e0011917, 2024
2024
Zika Virus Envelope Nanoparticle Antibodies Protect Mice without Risk of Disease Enhancement (vol 54, 102738, 2020)
R Shukla, RK Shanmugam, V Ramasamy, U Arora, G Batra, JA Acklin, ...
EBIOMEDICINE 66, 2021
2021
系統目前無法執行作業,請稍後再試。
文章 1–15